CD8A and neoplasm: Additionally, aDCM@PLGA (without RAPA) induced robust CD8+ activation, significantly enhanced the secretion of immune stimulatory cytokines (IL-2, IFN-γ, TNF-α, and IL-6) and suppressed orthotopic glioma growth in a prophylactic setup, suggesting its potential use as a cancer vaccine to induce tumor immunity (Figure 14A) [203].